Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × INDUSTRY × PT2385 × Clear all

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

von Hippel-Lindau Disease 1 Carcinoma, Renal Cell 1

Interventions

Paclitaxel 423 Carboplatin 373 Gemcitabine 345 Docetaxel 340 Cisplatin 311 Bevacizumab 299 pembrolizumab 283 Nivolumab 221 Pemetrexed 206 Capecitabine 200 Fluorouracil 181 Rituximab 177 Dexamethasone 177 Trastuzumab 167 Cyclophosphamide 163 Oxaliplatin 144 Erlotinib Hydrochloride 131 Prednisone 130 atezolizumab 128 Ipilimumab 125 Cetuximab 123 Irinotecan 122 Leucovorin 116 Doxorubicin 116 Bortezomib 105 Sorafenib 101 Sunitinib 95 Lenalidomide 95 Radiotherapy 82 Everolimus 82

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03108066 2024-09-24

MK-3795-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed

4 enrolled 11 charts

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡